Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL341648 | 0.94 | — | — | |
| Sulfuric Acid SCHEMBL22230398 | 0.94 | MEN1 (0.42) | MEN1ALDH1A1TSHRKMT2ATP53 | |
| Sulfuric Acid SCHEMBL288716 | 0.94 | MEN1 (0.42) | MEN1ALDH1A1TSHRKMT2ATP53 | |
| Sulfuric Acid SCHEMBL5907721 | 0.94 | MEN1 (0.42) | MEN1ALDH1A1TSHRKMT2ATP53 | |
| Sulfuric Acid SCHEMBL3291038 | 0.89 | MEN1 (0.39) | MEN1ALDH1A1TSHRKMT2ATP53 | |
| Sulfuric Acid SCHEMBL16974381 | 0.89 | MEN1 (0.39) | MEN1ALDH1A1TSHRKMT2ATP53 | |
| Sulfuric Acid SCHEMBL6268831 | 0.89 | MEN1 (0.39) | MEN1ALDH1A1TSHRKMT2ATP53 | |
| Sulfuric Acid SCHEMBL16974390 | 0.89 | MEN1 (0.39) | MEN1ALDH1A1TSHRKMT2ATP53 | |
| Sulfuric Acid SCHEMBL9188505 | 0.89 | MEN1 (0.39) | MEN1ALDH1A1TSHRKMT2ATP53 | |
| Sulfuric Acid SCHEMBL21052137 | 0.89 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1581194-B1 | MULTILAYERED TABLET CONTAINING PRAVASTATIN AND ASPIRIN AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2008-07-16 | — | — | EP | claimed |
| EP-1581194-A4 | MULTILAYERED TABLET CONTAINING PRAVASTATIN AND ASPIRIN AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2006-03-15 | — | — | EP | claimed |
| EP-1581194-A2 | MULTILAYERED TABLET CONTAINING PRAVASTATIN AND ASPIRIN AND METHOD | Bristol-Myers Squibb Company (US) | 2005-10-05 | — | — | EP | claimed |
| WO-2004052289-A2 | MULTILAYERED TABLET CONTAINING PRAVASTATIN AND ASPIRIN | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-06-24 | — | — | WO | claimed |
| US-20040115265-A1 | Multilayered tablet containing pravastatin and aspirin and method | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-17 | — | — | US | claimed |
| CN-119606990-A | Pharmaceutical formulation comprising tenofovir and emtricitabine | 吉利德科学公司 | 2025-03-14 | — | — | CN | disclosed |
| CN-115023446-A | Process for preparing catalyst and catalyst composition | 台塑工业美国公司 | 2022-09-06 | — | — | CN | disclosed |
| US-10857102-B2 | Therapeutic compositions comprising rilpivirine HCL and tenofovir disoproxil fumarate | GILEAD SCIENCES, INC. (US) | 2020-12-08 | — | — | US | disclosed |
| EP-3316869-A1 | PHARMACEUTICAL FORMULATIONS | Gilead Sciences, Inc. (US) | 2018-05-09 | — | — | EP | disclosed |
| US-9744137-B2 | Topiramate compositions and methods of enhancing its bioavailability | SUPERNUS PHARMACEUTICALS, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| US-20170027967-A1 | PHARMACEUTICAL FORMULATIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-02-02 | — | — | US | disclosed |
| WO-2017004012-A1 | PHARMACEUTICAL FORMULATIONS | GILEAD SCIENCES, INC. (US) | 2017-01-05 | — | — | WO | disclosed |
| EP-0178895-B1 | FLUIDIZED AND REHYDRATABLE MAGALDRATE COMPOSITIONS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1991-03-06 | — | — | EP | disclosed |
| EP-0183802-B1 | HIGH-DENSITY ANTACID POWDERS | REHEIS, INC. (US) | 1990-09-05 | — | — | EP | disclosed |
| US-4857324-A | Exogenously acidified antacid compositions having cytoprotective properties | AMERICAN HOME PRODUCTS CORPORATION (DEL.) (US) | 1989-08-15 | — | — | US | disclosed |
| US-4786502-A | CONTAINING A LIPID MATERIAL, DISPERSANT, EMULSIFIED AND A PHARMACEUTICAL ACTIVE MATERIAL; USEFUL IN TREATMENT OF GASTROINTESTINAL DISORDERS | THE PROCTER & GAMBLE COMPANY (US) | 1988-11-22 | — | — | US | disclosed |
| US-4704278-A | ANTACIDS | AMERICAN HOME PRODUCTS CORP (DEL) (US) | 1987-11-03 | — | — | US | disclosed |
| US-4676984-A | Rehydratable antacid composition | AMERICAN HOME PRODUCTS CORP. (US) | 1987-06-30 | — | — | US | disclosed |
| US-4639362-A | Process for the production of magaldrate | GIULINI CHEMIE GMBH (DE) | 1987-01-27 | — | — | US | disclosed |
| EP-0178895-A2 | Fluidized and rehydratable magaldrate compositions | AMERICAN HOME PRODUCTS CORPORATION (US) | 1986-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10857102-B2 | Therapeutic compositions comprising rilpivirine HCL and tenofovir disoproxil fumarate | SAMHD1, TYMP, CD4 | MEN1 3752/4885ALDH1A1 1820/4885TSHR 4028/4885 |
| US-20170027967-A1 | PHARMACEUTICAL FORMULATIONS | TPMT, SLC5A1, SLC28A1 | MEN1 3129/4885ALDH1A1 1253/4885TSHR 2987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.